ISDA

Deposition Date 2015-07-28

Release Date 2015-10-14

Last Version Date 2024-05-01

Entry Detail

PDB ID:

5AAU

Keywords:

SIGNALING PROTEIN

Title:

Optimization of a novel binding motif to to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist

Biological Source:

Source Organism:

HOMO SAPIENS (Taxon ID: 9606)

Host Organism:

ESCHERICHIA COLI

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.90 Å

R-Value Free:

0.22

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:ESTROGEN RECEPTOR
Gene (Uniprot):ESR1
Mutations:YES
Chain IDs:A, B
Chain Length:252
Number of Molecules:2
Biological Source:HOMO SAPIENS

UniProt ID:P03372 Pfam ID:PF00104

Ligand Molecules

XBR

Primary Citation

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-Fluoro-2-Methylpropyl)-3-Methyl-2, 3,4,9-Tetrahydro-1H-Pyrido[3,4-B]Indol-1-Yl)Phenyl)Acrylic Acid (Azd9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

De Savi, C, Bradbury, R.H, Rabow, A.A, Norman, R.A, De Almeida, C, Andrews, D.M, Ballard, P, Buttar, D, Callis, R, Currie, G.S, Davies, C, Donald, C, Feron, L, Hayter, B.R, Hussain, S, Karoutchi, G, Lamont, S, Macfaul, P.A, Moss, T.A, Pearson, S, Tonge, M, Walker, G, Weir, H, Wilson, Z, Weir, H.M, Bradbury, R.H, Lawson, M, Rabow, A.A, Buttar, D, Callis, R.J, Curwen, J.O, De Almeida, C, Ballard, P, Hulse, M, Donald, C.S, Feron, L.J.L, Karoutchi, G, Macfaul, P, Moss, T, Norman, R.A, Pearson, S.E, Tonge, M, Davies, G, Walker, G.E, Wilson, Z, Rowlinson, R, Powell, S, Sadler, C, Richmond, G, Ladd, B, Pazolli, E, Mazzola, A.M, D'Cruz, C, De Savi, C.Show

J.Med.Chem. 58 8128 ? (2015)

PMID: 26407012 DOI: 10.1021/ACS.JMEDCHEM.5B00984

Abstact

The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described. A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand. Aided by crystal structures of novel ligands bound to an ER construct, medicinal chemistry iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clinical candidate with high oral bioavailability across preclinical species that is currently being evaluated in phase I clinical trials for the treatment of advanced estrogen receptor (ER) positive breast cancer.

Legend

Protein

Chemical

Disease

Primary Citation of related structures